NCT03891420View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 9, 2020

Primary Completion Date

January 31, 2021

Study Completion Date

April 30, 2021

Conditions
COVID-19Yellow Fever
Interventions
DRUG

Galidesivir

Galidesivir IV infusion

DRUG

Placebo

Placebo IV infusion

Trial Locations (5)

Unknown

Hospital de Clinicas da Universidade Federal do Parana, Curitiba

Hospital Sao Vicente de Paulo-PPDS, Passo Fundo

Hospital Sao Lucas da Pucrs, Porto Alegre

Foundation Regional Faculty of Medicine of São José do Rio Preto, São José do Rio Preto

05403-010

Clinical Research Unit and Department of Infectious and Parasitic Diseases Hospital das Clínicas, School of Medicine, USP, São Paulo

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

BioCryst Pharmaceuticals

INDUSTRY

NCT03891420 - A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 | Biotech Hunter | Biotech Hunter